Research · Sep 3, 2026
[MMSI] Merit Medical Thesis 2026: A Cardiology-Radiology-Endoscopy Medical-Device Compounder Rides Vascular and OEM
Merit Medical Systems, Inc. (NASDAQ: MMSI), headquartered in South Jordan, Utah, is a cardiology-and-radiology-and-endoscopy-medical-device + emerging-cardiac-and-emerging-vascular-medical-device leader providing distinctive multi-cycle Merit-Medical-Systems Cardiovascular + Endoscopy + OEM medical-device services to US-and-international-Cardiologist + Vascular-Surgeon + Interventional-Radiologist + Gastroenterologist + Pediatric-Cardiologist + multi-cycle-OEM-medical-device-partner customer base. Distinctive multi-cycle Fred-Lampropoulos-and-Merit-Medical-Systems heritage: founded 1987 in South-Jordan-UT by Fred Lampropoulos; April 1992 NASDAQ Merit-Medical-Systems-IPO; 1992-2025 multi-cycle Merit-Medical-Systems + multi-cycle-disciplined-bolt-on-M&A; 2019 substantial Cianna-Medical-acquisition (~$200M breast-cancer-localization); 2024 substantial EmbolX-acquisition + 2024-2025 substantial Cook-Medical-Vascular-acquisition (~$200M). Multi-decade strategic-evolution: 1987-1992 Fred-Lampropoulos-Merit-Medical-Systems platform; April 1992 NASDAQ-IPO; 1992-2019 multi-cycle Merit-Medical-Systems + multi-cycle-disciplined-bolt-on-M&A; 2019 Cianna-Medical + 2024 EmbolX + 2024-2025 Cook-Medical-Vascular acquisitions; 2020-2025 substantial multi-cycle post-COVID + emerging-Cardiovascular-and-Vascular + emerging-Cook-Medical-Vascular + emerging-EmbolX + emerging-Endoscopy + emerging-international. Under founder-CEO Fred Lampropoulos (since 1987, ~38+ year founder-and-CEO + multi-cycle-Merit-Medical-Systems entrepreneur), FY2025 closes with selected various aggregate revenue ~$1.45-1.65B, adj. EBITDA ~$330-410M, adj. EPS ~$3.50-4.40, net debt ~$0.4-0.7B, and ~58-60M shares outstanding. The first deep-dive — Cardiovascular + Endoscopy + OEM medical-device franchise — covers entire cardiology-and-radiology-and-endoscopy-medical-device business + Merit-Medical-Systems-and-emerging-Merit-Medical-Systems positioning. Geographic + Facility composition: ~6,800+ employees: US (South-Jordan-UT-flagship + Pearland-TX + Aliso-Viejo-CA + multi-state); Europe (Galway-Ireland); Mexico + Singapore + China + emerging-multi-jurisdiction. Revenue mix: Cardiovascular ~70-80% (Peripheral-Intervention + Cardiac-Intervention + Custom-Procedural-Solutions + emerging-Vascular + emerging-Cook-Medical-Vascular + emerging-EmbolX + Cianna-Medical-breast-cancer-localization); Endoscopy ~10-15%; OEM ~10-15%. Customer base: US-and-international-Cardiologist + Vascular-Surgeon + Interventional-Radiologist + Gastroenterologist + Pediatric-Cardiologist + multi-cycle-OEM-medical-device-partner. 2019-Cianna-Medical (~$200M) + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisition (~$200M). Competes with Boston Scientific (BSX most-direct-larger-Boston-Scientific-Cardiovascular-comp), Medtronic (MDT), Abbott Laboratories (ABT), Edwards Lifesciences (EW most-direct-Edwards-Lifesciences-Cardiovascular-comp), Penumbra (PEN), Inari Medical (Stryker-acquired 2024), Becton Dickinson (BDX), Stryker (SYK), Johnson & Johnson (JNJ), Cook Medical (private + Cook-Medical-Vascular-divested-to-Merit-Medical-2024-2025), Terumo (4543-JP), Olympus (7733-JP + Endoscopy), HOYA (7741-JP + Pentax-Medical-Endoscopy), Fujifilm Holdings (4901-JP + Endoscopy), Karl Storz (private), Smith+Nephew (SN-LN), Globus Medical (GMED + NuVasive-merger-2023), Zimmer Biomet (ZBH), Mindray Medical (300760-CN), Siemens Healthineers (SHL-DE), GE HealthCare (GEHC), Philips Healthcare (PHIA-AS). The second deep-dive — Fred-Lampropoulos + 2024-2025-Cook-Medical-Vascular-Acquisition + multi-decade compounder thesis — covers Fred-Lampropoulos-founder-CEO + ~38+ year founder-and-CEO + multi-cycle-Merit-Medical-Systems expertise, April-1992-NASDAQ-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisition (~$200M) transformational-platform + multi-cycle-disciplined-bolt-on-M&A, emerging-US-and-international-Cardiovascular-and-Vascular + emerging-Endoscopy + emerging-Aging-Population structural-tailwinds. Multi-cycle-growth-and-emerging-investment-focused: no-regular-dividend + multi-cycle-modest-share-buyback. Multi-decade compounder thesis combines Fred-Lampropoulos-and-Merit-Medical-Systems ~38+ year heritage (founded 1987), ~6,800+ employees, April-1992-NASDAQ-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisitions + multi-cycle-disciplined-bolt-on-M&A, Fred Lampropoulos founder-CEO expertise, no-regular-dividend + multi-cycle-modest-share-buyback + IG-equivalent balance-sheet, emerging-US-and-international-Cardiovascular-and-Vascular + emerging-Cook-Medical-Vascular + emerging-Endoscopy + emerging-Aging-Population structural-tailwinds. Capital position is IG-equivalent (BB+/BBB-), no-regular-dividend, multi-cycle-modest-share-buyback: net debt ~$0.4-0.7B (~1.0-1.7x leverage), BB+/BBB-equivalent, $0.15-0.30B cash + undrawn revolver liquidity, FCF ~$220-300M/yr deployed into capex ~$60-110M/yr + no dividend + ~$25-75M/yr buyback + multi-cycle-disciplined-bolt-on-M&A + 2024-2025-Cook-Medical-Vascular-integration capex, ~58-60M shares. At ~$80-115 per share, equity value ~$4.7-6.9B, EV ~$5.1-7.6B, ~22-33x EPS and ~13-23x EV/EBITDA. Base case: Cardiovascular growth constructive + emerging-Cook-Medical-Vascular integration + emerging-EmbolX + emerging-Endoscopy + emerging-international + multi-cycle-disciplined-bolt-on-M&A + revenue $1.55-1.75B + adj. EBITDA $360-450M + adj. EPS $3.90-4.90 + multi-cycle-modest-share-buyback + ~5-15% return. Bull case: Cardiovascular growth accelerates + emerging-Cook-Medical-Vascular substantial-synergy + emerging-EmbolX inflects + emerging-Endoscopy inflects + emerging-international inflects + revenue $1.65-1.90B + adj. EBITDA $400-510M + adj. EPS $4.40-5.80 + multi-cycle-modest-share-buyback + selective-M&A + emerging-strategic-acquisition-target (Boston-Scientific + Medtronic + Abbott + Edwards-Lifesciences + Stryker + Johnson-and-Johnson + Becton-Dickinson + Terumo + private-equity-medical-device interest) + re-rate 25-40x + 25-50%+ return + takeout-premium-upside. Bear case: Cardiovascular growth stresses + emerging-Cook-Medical-Vascular-integration disappoints + emerging-Endoscopy disappoints + adj. EPS $2.20-2.80 + de-rate 15-22x + flat-to-substantially-negative.